Dyno Therapeutics reports 152-fold higher brain transduction than AAV9 in primates, plus new muscle and antibody-evasive capsid data.
Pfizer wins FDA approval for TALZENNA plus XTANDI in earlier metastatic prostate cancer. See how a 52% progression-risk reduction changes treatment.
Bayer's LYNKUET showed improved self-reported sleep quality in a post-hoc Phase 3 analysis. The findings do not establish a separate sleep indication.
Vir Biotechnology and Gilead Sciences have agreed to develop three dual-masked T-cell engager programmes under a deal worth up to approximately $1.88 billion. The $90 million upfront package includes cash and equity, while most of the headline value depends on future development and commercial milestones.
Avenzo's partner VelaVigo will disclose early human safety and efficacy findings for the Nectin-4/TROP2 antibody-drug conjugate VBC103 at ESMO Asia 2026. The presentation could clarify the clinical potential of dual-antigen targeting, while a separate United States study advances in urothelial cancer.
Chipscreen secures China IND clearance for CS43158, targeting FLT3 mutations and resistance pathways in acute myeloid leukemia.
Perceive Bio completes 94-eye VOY-101 enrollment for geographic atrophy. Examine trial design, safety, competition and the 2027 readout.
AviadoBio has reported dose-related increases in cerebrospinal fluid progranulin, including a 90% rise in its highest-dose cohort, alongside encouraging early safety and neurodegeneration biomarker findings. The 17-patient experience supports continued investigation of AVB-101, but evidence that the gene therapy slows dementia progression is still lacking.
AbCellera will reveal new ABCL635 safety and symptom data after reporting an 83% hot flash reduction. Can its antibody sustain the benefit?
Merck & Co.’s Keytruda plus Padcev has won a positive European regulatory opinion for perioperative treatment of resectable muscle-invasive bladder cancer regardless of cisplatin eligibility, potentially expanding an already important oncology franchise into a broader earlier-stage population.